Solanezumab for Preclinical Alzheimer's: Phase 3 Data

Solanezumab, a monoclonal antibody that binds to the monomeric or soluble form of amyloid-beta, is no better than placebo in slowing the progression of preclinical Alzheimer's, results of a phase 3 trial show.

Related Keywords

Massachusetts ,United States ,Bristol Myers Squibb ,Reisa Sperling ,Claire Sexton ,Eli Lilly ,Harvard Medical School ,Foundation For Neurologic Diseases ,Davis Alzheimer Prevention Program ,Alzheimer Association ,Alzheimer Research ,Albert Einstein College Of Medicine ,Alzheimer Association International Conference ,Genentech ,National Institute On ,Yugilbar Foundation ,Massachusetts General Hospital ,Medscape Medical ,Anti Amyloid Treatment ,Asymptomatic Alzheimer ,Association International Conference ,New England Journal ,Amyloid Accumulation ,Preclinical Alzheimer Cognitive Composite ,Cognitive Function Index ,Disease Cooperative Study Activities ,Daily Living Prevention Questionnaire ,Medscape Medical News ,National Institute ,Accelerating Medicines Partnership Through ,National Institutes ,Avid Radiopharmaceuticals ,Albert Einstein College ,Presented July ,